Trial · NCT07880600
Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
NCT07880600, Recruiting, Fujian Cancer Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer. Trials, record NCT07880600. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880600
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
- NCT number
- NCT07880600
- Status
- Recruiting
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Fujian Cancer Hospital
- Conditions
- Breast Neoplasm Female, Triple -Negative Breast Cancer
- Interventions
- Pre-treatment DCE-MRI-based AI model
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of pCR | After completion of neoadjuvant chemotherapy and definitive surgery (approximately 3-6 months after enrollment) | Compare the incidence of pathological complete response (pCR) among triple-negative breast cancer patients stratified as high chemotherapy benefit by pre-treatment DCE-MRI AI model against published historical control data to verify the predictive value of the imaging AI model. |
| Secondary | Objective response rate (ORR) of AI-defined high neoadjuvant chemotherapy benefit group | After completion of neoadjuvant chemotherapy and prior to definitive surgery (approximately 2-5 months after enrollment) | Compare the objective response rate (ORR) assessed by imaging after neoadjuvant chemotherapy before surgery in patients of AI-identified high chemotherapy benefit subgroup with historical control data. |
| Secondary | Between-subgroup differences in pCR rate | pCR result obtained after definitive surgical resection, approximately 3-6 months after enrollment | Compare pCR incidence between AI-stratified high benefit subgroup and low benefit subgroup. |
| Secondary | Between-subgroup differences in objective response rate (ORR) | After completion of neoadjuvant chemotherapy and prior to definitive surgery (approximately 2-5 months after enrollment) | Compare ORR between AI-stratified high benefit subgroup and low benefit subgroup. |
| Secondary | Disease-free survival (DFS) between high and low chemotherapy benefit subgroups | From the date of surgery until the first recurrence, metastasis, or death, whichever came first, assessed up to 60 months | Compare DFS (time interval from the date of surgery to first recurrence, metastasis or death) between AI-stratified high and low chemotherapy benefit subgroups to explore the correlation between AI imaging stratification and long-term survival prognosis. |
| Secondary | Overall survival (OS) between high and low chemotherapy benefit subgroups | From the date of surgery until death from any cause, assessed up to 60 months | Compare OS between AI-stratified high and low chemotherapy benefit subgroups to explore the correlation between AI imaging stratification and long-term survival prognosis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880600
GET https://conductscience.org/api/trials/v1/NCT07880600/registered